Instrument Inactif

Autres langues Motif Bio plc Nasdaq

Actions

MOTF BIO : BiVictriX Debuts on London's AIM Segment After $10 Million IPO	11/08/21
Motif Bio plc Announces Board Appointments	14/06/21
BiVictriX Therapeutics Ltd. cancelled the acquisition of Motif Bio plc in a reverse merger transaction.	14/06/21
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2020	10/05/21
Motif Bio : 2020 Annual Report and Accounts	10/05/21
Motif Bio plc Announces Board Changes	10/05/21
Orange Avenue Technologies LLC entered into a Stock Purchase Agreement to acquire Motif BioSciences, Inc. from Motif Bio plc	26/02/21
Motif Bio : Signs Reverse Takeover of Antibody-Drug Conjugate Company	27/01/21
BiVictriX Therapeutics Ltd. entered into a sale and purchase agreement to acquire Motif Bio plc for £5.5 million in a reverse merger transaction.	27/01/21
Motif Bio plc Reports Earnings Results for the Half Year Ended June 30, 2020	12/10/20
Motif Bio : Results of AGM	30/09/20
Motif Bio : Notification of Interim Results	23/09/20
Motif Bio : Annual Report and Accounts & Notice of AGM	09/09/20
Motif Bio plc Reports Earnings Results for the Full Year Ended December 31, 2019	01/09/20
Motif Bio : Delay in publication of Final Results	22/06/20
Motif Bio plc Announces Delay in Publication of Final Results for the Year Ended 31 December 2019	22/06/20
Motif Bio : Business Update and Appointment of Strategic Adviser	02/06/20
Motif Bio Appoints Adviser for Reverse Takeover Candidate	01/06/20
Motif Bio : Exercise of Warrants	18/05/20
Motif Bio : Placing to raise GBP650,000	06/05/20

Aucun résultat pour cette recherche